Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
Capricor Therapeutics (CAPR) Reports Q2 Loss of $0.59
August 6, 2019 4:54 PM EDTCapricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.59), versus ($1.42) reported last year. Revenue for the quarter came in at $410.35 thousand versus the consensus estimate of $231 thousand.
"This has been a very exciting quarter as we previously reported the outcome of our pre-specified... More
